Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $1.8 million.

  • Beam Therapeutics' Change in Account Payables fell 127.00% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 629.37%. This contributed to the annual value of $1.8 million for FY2024, which is 123.85% up from last year.
  • As of FY2024, Beam Therapeutics' Change in Account Payables stood at $1.8 million, which was up 123.85% from -$7.6 million recorded in FY2023.
  • Beam Therapeutics' 5-year Change in Account Payables high stood at $2.4 million for FY2022, and its period low was -$7.6 million during FY2023.
  • Its 3-year average for Change in Account Payables is -$1.1 million, with a median of $1.8 million in 2024.
  • In the last 5 years, Beam Therapeutics' Change in Account Payables spiked by 1,263.33% in 2021 and then slumped by 419.34% in 2023.
  • Over the past 5 years, Beam Therapeutics' Change in Account Payables (Yearly) stood at $60,000 in 2020, then soared by 1,263.33% to $818,000 in 2021, then spiked by 190.10% to $2.4 million in 2022, then slumped by 419.34% to -$7.6 million in 2023, then soared by 123.85% to $1.8 million in 2024.